Fresita Proteins Limited

Fresita Proteins Limited, formerly known as Sarda Proteins Limited, will convene a meeting of its Rights Issue Committee on Monday, October 26, 2026, to consider and decide on various matters related to a planned rights issue of equity shares, potentially raising up to Rs 90 crore. The rights issue is being conducted in accordance with the Companies Act, 2013, and the Securities and Exchange Board of India regulations, with the Rights Issue price, entitlement ratio, record date, and timing among the items to be discussed.

Fresita Proteins Ltd, formerly known as Sarda Proteins Limited, will close its trading window for designated persons and their immediate relatives from October 1, 2026, until 48 hours after the declaration of the company’s unaudited financial results for the quarter and half year ended September 30, 2026, in accordance with the SEBI (Prohibition of Insider Trading) Regulations, 2015.

Sarda Proteins Limited has officially changed its name to FRESITA PROTEINS LIMITED, effective August 21, 2026, following final approvals from the BSE Limited and the Ministry of Corporate Affairs (MCA). The company is in the process of updating its name with depositories NSDL and CDSL, and the scrip ID for the BOLT Plus system will be updated to “FRESITA” w.e.f September 21, 2026.

Sarda Proteins Limited announced that its board approved the convening of the 35th Annual General Meeting on Wednesday, September 30, 2026, at 11:00 A.M. (IST) via video conferencing or other audio-visual means, with a book closure from Thursday, September 24, 2026, to Wednesday, September 30, 2026, and a cut-off date of Wednesday, September 23, 2026, for determining voting eligibility.

Sarda Proteins Limited will hold a board meeting on Monday, September 7, 2026, at its corporate office to approve the date, time, and venue of the Annual General Meeting (AGM) and authorize the dispatch of the AGM notice to members, according to a regulatory filing with the BSE Limited.

Sarda Proteins Limited plans to raise up to Rs 10,000 crore through a rights issue of fully paid-up equity shares with a face value of Rs 10 each, as approved by the board on August 5, 2026; the rights issue will be offered to eligible shareholders as on a record date to be determined and notified later. The company has also approved a Draft Letter of Offer to be filed with SEBI and stock exchanges, and constituted a Rights Issue Committee to oversee the process, alongside appointing necessary intermediaries. Additionally, the board noted the resignation of non-executive director Gunvantray Jayantilal Zaladi, effective August 5, 2026, due to his inability to continue discharging his duties.

Shareholders overwhelmingly approved all resolutions at the company’s recent meeting, with votes in favor consistently reaching 81.6921% of votes polled, totaling 7,332,597 votes out of 8,975,900. Resolutions included the appointment and re-appointment of directors, approval of a related-party transaction and director remuneration, approval of a change in the objects clause, the appointment of a woman independent director, and the appointment of statutory auditors for both a casual vacancy and a five-year term. The high participation rate, with nearly 9 million votes polled for each resolution, indicates strong shareholder engagement, and promoters/promoter groups had no interest in any of the proposals.

Sarda Proteins Limited will seek board approval on Wednesday, August 05, 2026, to raise funds through the issuance of equity shares, convertible bonds, debentures, convertible warrants, preference shares, or other equity-linked securities via methods including rights issue, private placement, preferential issue, or qualified institutional placement, as permitted under applicable laws.

Sarda Proteins Limited held an Extraordinary General Meeting on Thursday, July 30, 2026, via video conferencing, where shareholders approved several resolutions including an increase in the authorized share capital from Rs 13,00,00,000 to Rs 1,00,00,00,000, an alteration of the Main Object Clause of the Memorandum of Association, and the regularization and appointment of directors including Mr. Shirish Dhirajlal Savaliya as Managing Director. Shareholders also approved a change of the company’s name from "Sarda Proteins Limited" to "Fresita Proteins Limited," subject to regulatory approvals, and the appointment of statutory auditors.

Net profit of Sarda Proteins reported to Rs 1.66 crore in the quarter ended June 2026 as against net loss of Rs 0.49 crore during the previous quarter ended June 2025. Sales rose 18.63% to Rs 12.99 crore in the quarter ended June 2026 as against Rs 10.95 crore during the previous quarter ended June 2025. ParticularsQuarter EndedJun. 2026Jun. 2025% Var. Sales12.9910.95 19 OPM %-25.17-4.47 - PBDT2.21-0.49 LP PBT2.21-0.49 LP NP1.66-0.49 LP Powered by Capital Market - Live